Increased MCP-1 and MIP-1beta in bronchoalveolar lavage fluid of chronic bronchitics

CC-chemokines are chemotactic factors expressed in a wide range of cell types and tissues. The aim of this study was to evaluate the involvement of CC-chemokines in the airways inflammation of patients affected by chronic bronchitis. The study evaluated, with an immunoassay, the concentrations of monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory protein-1alpha (MIP-1alpha) and macrophage inflammatory protein-1beta (MIP-1beta), in the bronchoalveolar lavage fluid (BALF) of 12 smokers affected by chronic bronchitis and 14 smoking, 15 nonsmoking and six exsmoking healthy subjects. MCP-1 was significantly increased in patients with chronic bronchitis ((mean+/-SD) 10.75+/-4.04 pg x mL(-1)) and in the smoker control group (12.39+/-5.87 pg x mL(-1)) compared with healthy exsmokers: (7.12+/-1.60 pg x mL(-1), p=0.035 and p=0.045, respectively) and nonsmokers (6.41+/-3.87 pg x mL(-1), p=0.003 and p=0.006, respectively). MIP-1alpha concentrations were undetectable. A significant difference was observed in MIP-1-beta levels in BALF of chronic bronchitics (8.11+/-5.97 pg x mL(-1)) compared to smoker (3.57+/-2.90 pg x mL(-1), p=0.018), exsmoker (3.43+/-0.68 pg x mL(-1), p=0.025) and nonsmoker (3.39+/-3.73 pg x mL(-1), p=0.008) control groups. A negative correlation was observed between MIP-1beta levels and forced expiratory volume in one second values (p=-0.64, p=0.035) in chronic bronchitics. An increase of monocyte chemotactic protein-1 is related to smoking habit and seems consistent with a lung inflammatory reaction. On the contrary, an increase in macrophage inflammatory protein-1beta levels is restricted to smokers developing chronic obstructive pulmonary disease. These data suggest a role of CC-chemokines in the pathogenesis of chronic bronchitis.

This article has been cited by other articles:

				K. F. Chung and I. M. Adcock Multifaceted mechanisms in COPD: inflammation, immunity, and tissue repair and destruction Eur. Respir. J., June 1, 2008; 31(6): 1334 - 1356. [Abstract] [Full Text] [PDF]

				I. Sabroe, L. C. Parker, S. K. Dower, and M. K. B. Whyte Practical and Conceptual Models of Chronic Obstructive Pulmonary Disease Proceedings of the ATS, December 1, 2007; 4(8): 606 - 610. [Abstract] [Full Text] [PDF]

				J. L. Curtis, C. M. Freeman, and J. C. Hogg The Immunopathogenesis of Chronic Obstructive Pulmonary Disease: Insights from Recent Research Proceedings of the ATS, October 1, 2007; 4(7): 512 - 521. [Abstract] [Full Text] [PDF]

				C. M. Freeman, J. L. Curtis, and S. W. Chensue CC Chemokine Receptor 5 and CXC Chemokine Receptor 6 Expression by Lung CD8+ Cells Correlates with Chronic Obstructive Pulmonary Disease Severity Am. J. Pathol., September 1, 2007; 171(3): 767 - 776. [Abstract] [Full Text] [PDF]

				P. J. Barnes, B. Chowdhury, S. A. Kharitonov, H. Magnussen, C. P. Page, D. Postma, and M. Saetta Pulmonary Biomarkers in Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., July 1, 2006; 174(1): 6 - 14. [Abstract] [Full Text] [PDF]

				R O'Donnell, D Breen, S Wilson, and R Djukanovic Inflammatory cells in the airways in COPD Thorax, May 1, 2006; 61(5): 448 - 454. [Abstract] [Full Text] [PDF]

				S. Kubo, M. Kobayashi, Y. Masunaga, H. Ishii, Y. Hirano, K. Takahashi, and Y. Shimizu Cytokine and chemokine expression in cigarette smoke-induced lung injury in guinea pigs Eur. Respir. J., December 1, 2005; 26(6): 993 - 1001. [Abstract] [Full Text] [PDF]

				W. MacNee Pathogenesis of Chronic Obstructive Pulmonary Disease Proceedings of the ATS, November 1, 2005; 2(4): 258 - 266. [Abstract] [Full Text] [PDF]

				P. J. Barnes Mediators of Chronic Obstructive Pulmonary Disease Pharmacol. Rev., December 1, 2004; 56(4): 515 - 548. [Abstract] [Full Text] [PDF]

				A. Di Stefano, A. Capelli, and C. F. Donner Role of Interleukin-8 in the Pathogenesis and Treatment of COPD Chest, September 1, 2004; 126(3): 676 - 678. [Full Text] [PDF]

				S. L. Traves, S. J. Smith, P. J. Barnes, and L. E. Donnelly Specific CXC but not CC chemokines cause elevated monocyte migration in COPD: a role for CXCR2 J. Leukoc. Biol., August 1, 2004; 76(2): 441 - 450. [Abstract] [Full Text] [PDF]

				A. Di Stefano, G. Caramori, A. Capelli, I. Gnemmi, F.L. Ricciardolo, T. Oates, C.F. Donner, K.F. Chung, P.J. Barnes, and I.M. Adcock STAT4 activation in smokers and patients with chronic obstructive pulmonary disease Eur. Respir. J., July 1, 2004; 24(1): 78 - 85. [Abstract] [Full Text] [PDF]

				I. R. Witherden, E. J. Vanden Bon, P. Goldstraw, C. Ratcliffe, U. Pastorino, and T. D. Tetley Primary Human Alveolar Type II Epithelial Cell Chemokine Release: Effects of Cigarette Smoke and Neutrophil Elastase Am. J. Respir. Cell Mol. Biol., April 1, 2004; 30(4): 500 - 509. [Abstract] [Full Text] [PDF]

				B.W.M. Willemse, D.S. Postma, W. Timens, and N.H.T. ten Hacken The impact of smoking cessation on respiratory symptoms, lung function, airway hyperresponsiveness and inflammation Eur. Respir. J., March 1, 2004; 23(3): 464 - 476. [Abstract] [Full Text] [PDF]

				P.J. Barnes, S.D. Shapiro, and R.A. Pauwels Chronic obstructive pulmonary disease: molecular and cellularmechanisms Eur. Respir. J., October 1, 2003; 22(4): 672 - 688. [Abstract] [Full Text] [PDF]

				A. Di Stefano, G. Caramori, T. Oates, A. Capelli, M. Lusuardi, I. Gnemmi, F. Ioli, K.F. Chung, C.F. Donner, P.J. Barnes, et al. Increased expression of nuclear factor-{kappa}B in bronchial biopsies from smokers and patients with COPD Eur. Respir. J., September 1, 2002; 20(3): 556 - 563. [Abstract] [Full Text] [PDF]

				S L Traves, S V Culpitt, R E K Russell, P J Barnes, and L E Donnelly Increased levels of the chemokines GRO{alpha} and MCP-1 in sputum samples from patients with COPD Thorax, July 1, 2002; 57(7): 590 - 595. [Abstract] [Full Text] [PDF]

				W. I. de Boer Cytokines and Therapy in COPD* : A Promising Combination? Chest, May 1, 2002; 121(5_suppl): 209S - 218S. [Abstract] [Full Text] [PDF]